Clinical Trials

492 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Multiple Myeloma, Recurrence

NCT04181827 2026-04-13

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT05083169 2026-04-13

MajesTEC-3

587 enrolled 2 FDA

Multiple Myeloma

NCT05438043 2026-04-13

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT04162210 2026-03-31

DREAMM-3

325 enrolled 10 charts

Multiple Myeloma

NCT05020236 2026-03-27

MAGNETISMM-5

944 enrolled

Multiple Myeloma

NCT06413498 2026-03-27

iMMagine-3

450 enrolled

Multiple Myeloma

NCT07452198 2026-03-25

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

358 enrolled

Multiple Myeloma

NCT05519085 2026-03-24

SUCCESSOR-1

810 enrolled

Multiple Myeloma, Recurrence

NCT06158841 2026-03-13

CERVINO

380 enrolled

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

795 enrolled

Multiple Myeloma

NCT07391657 2026-03-12

DURGA-4

508 enrolled

Multiple Myeloma

NCT05730036 2026-03-06

LINKER-MM3

410 enrolled

Multiple Myeloma

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

228 enrolled

Multiple Myeloma, Recurrence

NCT05675319 2026-01-05

AlloRelapseMM

28 enrolled

Multiple Myeloma

NCT03180736 2025-12-19

EMN14

304 enrolled 19 charts 2 FDA

Multiple Myeloma

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

117 enrolled

Multiple Myeloma

NCT06464991 2025-07-20

FUMANBA-03

240 enrolled

Multiple Myeloma

NCT06508983 2025-06-27

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

360 enrolled

Multiple Myeloma

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT06956170 2025-06-11

DREAMM 8

21 enrolled 9 charts

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

302 enrolled 10 charts

Multiple Myeloma

NCT02990338 2025-01-17

ICARIA-MM

307 enrolled 32 charts 3 FDA

Phase 3 Not yet recruiting

Multiple Myeloma

NCT06742138 2024-12-19

To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

284 enrolled

Multiple Myeloma

NCT06232707 2024-05-31

ALUMMINATE

Phase 3 Withdrawn

Multiple Myeloma, Recurrence

NCT03151811 2024-01-30

OCEAN

495 enrolled 15 charts

Multiple Myeloma

NCT01734928 2023-06-06

OPTIMISMM

559 enrolled 16 charts

Multiple Myeloma

NCT02726581 2023-03-27

CheckMate 602

170 enrolled 16 charts

Multiple Myeloma

NCT03651128 2022-12-15

KarMMa-3

381 enrolled

Multiple Myeloma, Recurrence

NCT05236621 2022-02-11

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 3 Unknown

85 enrolled

Multiple Myeloma, Recurrence

NCT01712789 2022-01-10

STRATUS

682 enrolled 23 charts

Multiple Myeloma, Recurrence

NCT02576977 2021-10-08

KEYNOTE 183

251 enrolled 17 charts

Multiple Myeloma

NCT03440411 2021-03-10

PO-3887

9 enrolled 20 charts

Multiple Myeloma

NCT01324947 2019-11-19

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

74 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01311687 2018-10-24

NIMBUS

455 enrolled 38 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02916420 2016-11-02

Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma

Phase 3 Unknown

73 enrolled